rss
J Clin Pathol 2006;59:10-16 doi:10.1136/jcp.2005.027664
  • Review

Altered metabolism and mitochondrial genome in prostate cancer

  1. G D Dakubo1,
  2. R L Parr1,
  3. L C Costello2,
  4. R B Franklin2,
  5. R E Thayer1
  1. 1Genesis Genomics Inc, 1294 Balmoral Street, Thunder Bay, Ontario, Canada, P7B 5Z5
  2. 2Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore, Maryland 21201, USA
  1. Correspondence to:
 Dr G D Dakubo
 Genesis Genomics Inc, 1294 Balmoral Street, Thunder Bay, Ontario, Canada, P7B 5Z5; gabriel.dakubo{at}genesisgenomics.com
  • Accepted 17 May 2005

Abstract

Mutations in mitochondrial DNA are frequent in cancer and the accompanying mitochondrial dysfunction and altered intermediary metabolism might contribute to, or signal, tumour pathogenesis. The metabolism of human prostate peripheral zone glandular epithelial cells is unique. Compared with many other soft tissues, these glandular epithelial cells accumulate high concentrations of zinc, which inhibits the activity of m-aconitase, an enzyme involved in citrate metabolism through Krebs cycle. This causes Krebs cycle truncation and accumulation of high concentrations of citrate to be secreted in prostatic fluid. The accumulation of zinc also inhibits terminal oxidation. Therefore, these cells exhibit inefficient energy production. In contrast, malignant transformation of the prostate is associated with an early metabolic switch, leading to decreased zinc accumulation and increased citrate oxidation. The efficient energy production in these transformed cells implies increased electron transport chain activity, increased oxygen consumption, and perhaps, excess reactive oxygen species (ROS) production compared with normal prostate epithelial cells. Because ROS have deleterious effects on DNA, proteins, and lipids, the altered intermediary metabolism may be linked with ROS production and accelerated mitochondrial DNA mutations in prostate cancer.

Footnotes

  • Genesis Genomics Inc (GGI) supported this work. GDD, RLP, and RET hold stock options and equity ownership in GGI, and are employed by GGI

Latest from JCP Education

Latest from JCP Education

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Free archive
The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest Pathology jobs

    Latest Pathology jobs